文献速递淋巴瘤

循环肿瘤DNA预测套细胞淋巴瘤的治疗结局

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

这项前瞻性2期研究分析了53例初治套细胞淋巴瘤患者在接受硼替佐米联合DA-EPOCH-R诱导治疗及后续随机分配观察或硼替佐米维持治疗过程中的循环肿瘤DNA动态。中位随访12.7年,诱导2周期后无可检测ctDNA的患者无进展生存期和总生存期均优于可检测者,而硼替佐米窗口期ctDNA动态无预后价值,硼替佐米维持治疗未改善PFS或OS。

要点

  • 诱导2周期后ctDNA阴性者中位PFS 2.7年 vs 可检测者1.8年(总体P=0.005)。
  • 诱导2周期后ctDNA阴性者中位OS 13.8年 vs 可检测者7.4年(总体P=0.03)。
  • 硼替佐米窗口期ctDNA动态无预后价值,硼替佐米维持未改善PFS或OS。

核心结论

  • 诱导治疗期间ctDNA阴性强烈与生存改善相关,支持研究应答 adapted 策略。

研究设计与样本

  • 前瞻性2期研究,纳入53例初治套细胞淋巴瘤患者,接受硼替佐米联合DA-EPOCH-R诱导治疗6周期,缓解者随机分配至观察或硼替佐米维持治疗,多数患者诱导前接受硼替佐米单药初始治疗窗口。
  • 中位随访12.7年,在治疗前、窗口期后、第1和2周期后、诱导结束时及每次随访时采集血清,采用下一代测序定量免疫球蛋白受体序列编码的ctDNA作为微小残留病标志物。

主要发现

  • 诱导2周期后无可检测ctDNA的患者较可检测者中位PFS延长(2.7年 vs 1.8年,总体P=0.005),中位OS亦延长(13.8年 vs 7.4年,总体P=0.03)。
  • 硼替佐米窗口期ctDNA动态无预后价值,硼替佐米维持治疗组与观察组PFS或OS无差异。
  • 诱导后ctDNA监测显示部分病例分子学复发先于临床复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is biologically and clinically heterogeneous and would benefit from prognostic biomarkers to guide management. Circulating tumor DNA (ctDNA) is a novel prognostic biomarker in diffuse large B-cell lymphoma that may have applicability in MCL. We analyzed ctDNA dynamics in previously untreated patients with MCL who received induction therapy with bortezomib and DA-EPOCH-R for 6 cycles followed by random assignment to observation or bortezomib maintenance in responding patients in a prospective phase 2 study. Most patients also underwent initial treatment window of bortezomib alone prior to induction. Serum was collected pretreatment, after the window, after cycles 1 and 2, at the end of induction, and at each follow-up visit along with restaging computed tomography scans. Next-generation sequencing was used to identify and quantify ctDNA encoding the immunoglobulin receptor sequences in serum as markers of minimal residual disease. Fifty-three patients were enrolled, with a median follow-up of 12.7 years. Patients without detectable ctDNA after 2 cycles of induction had longer progression-free survival (PFS) and overall survival (OS) compared with those with detectable ctDNA (median PFS, 2.7 vs 1.8 years; overall P = .005; median OS, 13.8 vs 7.4 years; overall P = .03). Notably, in vivo assessment of ctDNA dynamics during the bortezomib window was not prognostic, and there was no difference in PFS or OS with bortezomib maintenance. ctDNA monitoring after induction showed that molecular relapse preceded clinical relapse in some cases. In conclusion, interim ctDNA negativity strongly correlates with improved survival and supports the investigation of response-adapted strategies. This trial was registered at www.clinicaltrials.gov as #NCT00114738.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lakhotia R, Melani C, Dunleavy K, et al. Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Adv. 2022. PMID: 35143622. doi:10.1182/bloodadvances.2021006397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。